Brainscan SA
8.00
PLN
-0.70
(-8.05%)
ISIN
PLBRNSN00016
Return %
Stock
S&P 500
1Y
-65.52
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Full Time Employees
- 11
- Sector
- Technology services
- Industry
- Information technology services
- Address
- Gdansk Poland
- IPO Date
- May 15, 2024
- Website
- brainscan.ai
- Similar Companies
- Business
- Brainscan S.A. is a medical technology company that specializes in artificial intelligence software solutions for automated diagnostic imaging and clinical neuroradiology. The company develops and commercializes deep learning-based decision support systems designed to assist radiologists, emergency physicians, and neurologists in analyzing non-contrast head computed tomography (CT) scans. Its flagship software platform, BrainScan CT, automatically detects, segments, and classifies intracranial pathologies across multiple core clinical categories: acute hemorrhages and vascular lesions, including epidural hematomas, subdural hematomas, subarachnoid hemorrhages, intracerebral hemorrhages, and brain aneurysms; ischemic strokes, brain infarcts, and early signs of ischemia; cranial fractures, midline shifts, and brain herniation mass effects; and primary or metastatic intracranial neoplasms. The platform provides comprehensive clinical workflow integration and diagnostic tools, including automated lesion volume quantification and anatomical localization; structured radiology draft report generation; triage prioritization with visual heatmap alerts and infographic overlays; DICOM-compliant PACS and RIS integration; and flexible deployment configurations via secure cloud-based infrastructures or on-premise hospital server architectures. Brainscan S.A. primarily serves hospitals, emergency medical centers, trauma facilities, outpatient diagnostic imaging networks, and commercial teleradiology providers across Poland and international markets. In recent operational developments, Brainscan S.A. completed its public debut on the Warsaw Stock Exchange NewConnect market in May 2024 under the ticker symbol BSN. In December 2025, the company entered into a commercial distribution partnership with Czech medical AI provider Carebot s.r.o. to accelerate international market penetration across Central and Eastern Europe. Brainscan S.A. secured a 2.64 million euro research and development grant under the SMART Pathway program administered by the Polish Agency for Enterprise Development to finance the development of a multimodal automated brain pathology diagnostic system running through 2027. In addition, the company maintains active clinical validation partnerships with medical institutions including the LMU Hospital in Munich and the Provincial Hospital in Poznan, holds CE Medical Device Regulation (MDR 2017/745) certification for European distribution, and is actively pursuing U.S. Food and Drug Administration (FDA) clearance to support entry into North American healthcare markets. Brainscan S.A. was founded in 2016 and is headquartered in Gdansk, Poland.